British Dragon
British Dragon
Tamoxifen 20 mg
Product Information
Compound Details
Active Substance
Tamoxifen Citrate
Selective Estrogen Receptor Modulator (SERM)
20 mg
Strength
20 mg/tablet
Package
50 or 100 Tablets
1,000 mg or 2,000 mg Total Labeled Content
Form
Oral Tablets
Drug Class
SERM
Selective Estrogen Receptor Modulator
Estimated Half-Life
Approximately 5–7 Days
Manufacturer
British Dragon
Amount :
50 tabs
100 tabs
Shipping :
International
U.S. Domestic
Out of stock
- Overview
- Profile
- Usage
- Safety
- Shipping
- Storage
- FAQ
- Reviews
Product Overview
Tamoxifen 20 mg by British Dragon
Tamoxifen 20 mg is an oral tamoxifen citrate tablet manufactured by British Dragon and dosed at 20 mg per tablet, supplied in packs of 50 or 100 tablets.
Tamoxifen Citrate Oral
Tamoxifen 20 mg contains tamoxifen citrate, a selective estrogen receptor modulator (SERM) that has been used clinically for decades. Tamoxifen works by competitively binding to estrogen receptors, blocking estrogen's effects in certain tissues such as breast tissue. In medical practice, tamoxifen is FDA-approved for the treatment of metastatic breast cancer in women and men, adjuvant therapy for node-positive breast cancer, and reduction of breast cancer incidence in high-risk women.
Tamoxifen is extensively metabolized after oral administration, with a terminal elimination half-life of approximately 5 to 7 days. Following a single oral dose of 20 mg, peak plasma concentrations occur approximately 5 hours after dosing, and steady-state concentrations are achieved in about 4 weeks with daily use. The drug is metabolized primarily by cytochrome P450 enzymes, including CYP3A, 2C9, and 2D6.
In non-medical bodybuilding and performance-enhancement contexts, tamoxifen is commonly referenced as a component of post-cycle therapy (PCT) to help restore endogenous testosterone production and manage estrogenic side effects. A 1989 case series described bodybuilders using tamoxifen for self-treatment of gynecomastia associated with anabolic steroid use. However, clinical guidelines explicitly state that tamoxifen use by athletes for performance purposes is not recommended and carries risks including venous thromboembolism and endometrial cancer. Such use falls outside approved indications.
Key Properties of Tamoxifen 20 mg
- FDA-approved selective estrogen receptor modulator (SERM)
- Blocks estrogen receptors in breast tissue to reduce breast cancer risk
- Long half-life of approximately 5 to 7 days supports once-daily dosing
- 20 mg tablet matches standard clinical dosage strength
- 50 or 100 tablet pack sizes support research protocols
Product Profile
Tamoxifen Citrate Profile
Tamoxifen citrate is a selective estrogen receptor modulator that competitively binds to estrogen receptors, acting as an antagonist in breast tissue and a partial agonist in other tissues.
Selective Estrogen Receptor Modulator
Tamoxifen is a non-steroidal selective estrogen receptor modulator (SERM) that has been approved by the FDA for breast cancer treatment since the 1970s. The drug works by competitively binding to estrogen receptors, thereby blocking the effects of endogenous estrogens. In breast tissue, tamoxifen acts as an estrogen antagonist, reducing the proliferation of estrogen-dependent cancer cells.
In the NSABP P-1 trial, tamoxifen reduced the incidence of invasive breast cancer by 44% in high-risk women after a median follow-up of 4.2 years. Another study showed that women with ductal carcinoma in situ (DCIS) who took tamoxifen lowered their risk of invasive breast cancer by 43%.
In non-medical bodybuilding contexts, tamoxifen is used as part of PCT to block estrogen receptors in breast tissue and stimulate LH and FSH release through its antagonist action at the pituitary. The recommended non-medical PCT dosage is typically 20 mg daily for 4 to 6 weeks.
Clinical Status
FDA-Approved for Breast Cancer — Not for Performance Use
Tamoxifen is FDA-approved for metastatic breast cancer, adjuvant therapy, and risk reduction in high-risk women. Clinical guidelines explicitly state that approved indications in male athletes do not exist and its use carries venous thromboembolism and endometrial cancer risks.
Tamoxifen 20 mg vs Other British Dragon Preparations
British Dragon offers several ancillary compounds used in non-medical bodybuilding contexts. Clomiphene is another SERM commonly referenced for PCT, while Anastrozole and Exemestane are aromatase inhibitors used to manage estrogenic side effects during cycles.
Tamoxifen's distinguishing characteristic among these compounds is its dual mechanism: blocking estrogen receptors in breast tissue while acting as an estrogen agonist in the liver and bone. A 1989 case series described bodybuilders using tamoxifen for self-treatment of gynecomastia associated with anabolic steroid use.
Dosage & Usage
Tamoxifen 20 mg Dosage & Usage
The information below is provided for educational reference only. Tamoxifen is a prescription medication; medical use requires appropriate diagnosis, clinical supervision, and ongoing monitoring. Non-medical use falls outside approved indications.
Typical Dosage Ranges
In clinical practice, tamoxifen dosing varies by indication. For metastatic breast cancer in women and men, the recommended dose is 20 to 40 mg daily, with doses exceeding 20 mg daily given in divided doses morning and evening. For adjuvant treatment of node-positive breast cancer in women, the recommended dose is 20 mg daily for 5 years. For reduction of breast cancer incidence in high-risk women, the recommended dose is 20 mg daily for 5 years.
In non-medical bodybuilding contexts, tamoxifen is commonly referenced at 20 mg daily for 4 to 6 weeks during PCT, with some users describing protocols of 40 mg daily for the first two weeks followed by 20 mg daily.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Clinical (metastatic breast cancer) | 20–40 mg | Daily, divided if >20 mg |
| Clinical (adjuvant therapy) | 20 mg | Daily for 5 years |
| Clinical (risk reduction) | 20 mg | Daily for 5 years |
| Non-medical (PCT, reported) | 20–40 mg | Daily for 4–6 weeks |
These non-medical ranges represent community-reported practices and are not derived from controlled clinical trials for performance enhancement. Tamoxifen's long half-life of approximately 5 to 7 days allows for flexible dosing timing.
Stacking & Cycle Considerations
In non-medical bodybuilding contexts, tamoxifen is typically used as a standalone PCT compound rather than being stacked with other agents. It is commonly referenced alongside Clomiphene as an alternative SERM, with some protocols describing the use of one or the other rather than both simultaneously.
Clinical research supports the use of tamoxifen for restoring the pituitary-gonadal axis after suppression. In the NSABP P-1 trial, tamoxifen demonstrated a favorable safety profile for its approved indications.
Managing Side Effects
Common side effects of tamoxifen include hot flashes, vaginal discharge, and irregular menstrual periods. Serious but less common side effects include blood clots in veins or lungs, stroke, endometrial cancer, uterine sarcoma, and cataracts.
In the NSABP P-1 trial, among women with an intact uterus, tamoxifen doubled the chance of developing endometrial cancer from 1 in 1000 to 2 in 1000 per year. The risk of blood clots was also increased in women taking tamoxifen.
Important
Individual Response Varies
Tamoxifen has approved dosing for specific medical indications. Any information about non-medical use is derived from user-reported practices and is not validated by controlled clinical research. This information does not constitute medical advice.
Safety & Information
Tamoxifen Citrate Safety Information
Tamoxifen is a prescription medication with known risks that require clinical oversight. It carries boxed warnings for endometrial cancer and thromboembolic events.
Important Safety Information
Tamoxifen carries serious risks including increased incidence of uterine malignancies (endometrial cancer and uterine sarcoma), which have been reported in association with tamoxifen treatment. In the NSABP P-1 trial, there was a statistically significant increase in the incidence of endometrial cancer among participants randomized to tamoxifen compared to placebo.
Tamoxifen also increases the risk of blood clots in veins or lungs and stroke. These can cause serious problems, including death. Blood clots may occur up to 2 to 3 months after stopping tamoxifen. Tamoxifen should not be taken by women who are pregnant or breastfeeding, as it may harm the unborn baby.
Important
Non-Medical Use
Non-medical use of tamoxifen falls outside approved indications. Clinical guidelines explicitly state that approved indications in male athletes do not exist, and use carries serious risks. Product purity does not establish that non-medical use is safe or appropriate.
Potential Adverse Effects
The most common side effect of tamoxifen is hot flashes, which is not a sign of a serious problem. The next most common side effect is vaginal discharge; if the discharge is bloody, it could be a sign of a serious problem.
Less common but serious side effects include changes in the endometrium or body of the uterus (endometrial cancer), blood clots in veins or lungs, stroke, cataracts or increased chance of needing cataract surgery, and liver problems including jaundice.
Other potential side effects include hypercalcemia in breast cancer patients with bone metastases. In the NSABP P-1 trial, tamoxifen increased the risk of developing cataracts or needing cataract surgery.
Conditions Requiring Medical Evaluation
Tamoxifen is not appropriate for everyone. It should not be taken to reduce breast cancer risk if the patient has ever had a blood clot needing medical treatment, is taking blood thinners, has limited mobility, or is at high risk for blood clots. Tamoxifen is contraindicated in pregnancy and breastfeeding.
Patients with a history of endometrial cancer, uterine sarcoma, or other serious conditions should discuss these with their healthcare provider before considering tamoxifen.
Monitoring During Therapy
Medically supervised tamoxifen therapy involves regular monitoring for signs of endometrial cancer, blood clots, and liver problems. Patients should report signs of changes in the uterus including vaginal bleeding, change in monthly bleeding, or pelvic pain. Signs of blood clots include sudden chest pain, shortness of breath, coughing up blood, or pain/tenderness/swelling in one or both legs.
Signs of stroke include sudden weakness or numbness, confusion, trouble seeing, trouble walking, or severe headache. Slow blurring of vision may indicate cataracts.
Product Care
Storage & Handling
Store tablets in a cool, dry place in the original packaging. Keep out of reach of children. Swallow tablets whole with water or another non-alcoholic liquid. Tamoxifen can be taken with or without food. Inspect tablets before use and do not use if they appear damaged or compromised.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
Tamoxifen 20 mg is supplied through the official British Dragon distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official British Dragon distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Tamoxifen 20 mg product, use the security code on the packaging and cross-check it on the British Dragon official site. Official British Dragon presentation and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Tamoxifen 20 mg Storage
Proper storage conditions help preserve tablet stability and overall product integrity throughout shelf life.
Recommended Conditions
Store at controlled room temperature (15–25°C) in a cool, dry place, away from direct light and moisture. Keep tablets in their original packaging until use to protect from humidity.
Inspect tablets before use and do not use if they appear discolored, cracked, or otherwise compromised. Keep out of reach of children.
Quick Reference
Do & Don't
- Do store at 15–25°C
- Do keep in original packaging
- Do inspect before each use
- Don't expose to direct sunlight or moisture
- Don't store in bathroom or humid areas
- Don't use if tablets appear abnormal
Frequently Asked Questions
Tamoxifen 20 mg FAQ
Answers to common questions about Tamoxifen 20 mg, the Tamoxifen Citrate compound, and its applications.
What is Tamoxifen 20 mg used for?
Tamoxifen 20 mg contains tamoxifen citrate, a selective estrogen receptor modulator (SERM). In clinical medicine, it is FDA-approved for metastatic breast cancer, adjuvant therapy, and reduction of breast cancer incidence in high-risk women. In non-medical bodybuilding contexts, it is commonly referenced as a component of post-cycle therapy (PCT), though such use falls outside approved indications.
How often should Tamoxifen 20 mg be taken?
The clinical dose for breast cancer treatment is 20 to 40 mg daily, with doses exceeding 20 mg given in divided doses. For risk reduction, the dose is 20 mg daily for 5 years. In non-medical contexts, tamoxifen is commonly referenced at 20 mg daily for 4 to 6 weeks during PCT. These non-medical practices are not derived from controlled clinical trials.
Does Tamoxifen 20 mg require PCT?
Tamoxifen is itself used as a post-cycle therapy (PCT) compound rather than requiring PCT after use. It is not an anabolic steroid and does not suppress endogenous testosterone production. Instead, it acts as an estrogen receptor antagonist in the pituitary, stimulating LH and FSH release to help restore the pituitary-gonadal axis after suppression.
What does Tamoxifen Citrate do?
Tamoxifen competitively binds to estrogen receptors, blocking estrogen's effects in breast tissue. In the NSABP P-1 trial, tamoxifen reduced the incidence of invasive breast cancer by 44% in high-risk women. It has a terminal elimination half-life of approximately 5 to 7 days, supporting once-daily dosing.
How long does Tamoxifen take to work?
After initiation of therapy, steady-state concentrations for tamoxifen are achieved in about 4 weeks, and steady-state concentrations for its major metabolite N-desmethyl tamoxifen are achieved in about 8 weeks. Clinical effects on breast cancer risk reduction are typically observed over years of treatment.
Is Tamoxifen the best SERM for PCT?
There is no universally established "best" SERM, and tamoxifen has not been validated in controlled trials specifically for post-steroid-cycle recovery. Clinical guidelines explicitly state that approved indications in male athletes do not exist and its use carries serious risks. Clomiphene is an alternative SERM commonly referenced in non-medical PCT contexts.
What is the difference between Tamoxifen and Clomiphene?
Tamoxifen and Clomiphene are both SERMs but have different receptor activity profiles and clinical applications. Tamoxifen is primarily used for breast cancer treatment and risk reduction, while clomiphene is used for ovulation induction. Tamoxifen acts as an estrogen agonist in the liver and bone, while clomiphene's activity profile differs.
What is the difference between Tamoxifen and Anastrozole?
Tamoxifen and Anastrozole have different mechanisms. Tamoxifen is a SERM that blocks estrogen receptors, while anastrozole is an aromatase inhibitor that reduces estrogen synthesis by blocking androgen-to-estrogen conversion. They are used for different purposes in non-medical contexts.
Is 20 mg of Tamoxifen a lot?
Tamoxifen 20 mg is labeled at 20 mg of tamoxifen citrate per tablet. This is the standard clinical dose for adjuvant breast cancer therapy and risk reduction. In non-medical PCT contexts, 20 mg daily is commonly referenced as a standard dose.
What strength is Tamoxifen 20 mg?
Tamoxifen 20 mg is labeled at 20 mg of tamoxifen citrate per tablet. It is supplied as oral tablets in packs of 50 or 100 tablets manufactured by British Dragon.
Is Tamoxifen 20 mg lab tested?
No lab reports were provided for this specific product listing. For products with published laboratory reports, those results would apply to the specific tested sample and should not be interpreted as a measurement of every tablet or production batch.
Related Offers
British Dragon Pharmaceuticals
Product Information Compound Details
Active Substance Anastrozole Nonsteroidal Aromatase Inhibitor
1 mgStrength 1 mg/tablet
Package 50 or 100 Tablets
Form Oral Tablets
Drug Class Aromatase Inhibitor
Inhibitor Type Nonsteroidal
Manufacturer British Dragon
Lab Tested
British Dragon Pharmaceuticals
Product Information Compound Details
Active Substance Testosterone Enanthate Long-acting testosterone ester
250 mg/mLStrength 250 mg/mL
Package 10 mL Vial 2,500 mg total labeled content
Form Oil-Based Injectable
Estimated Half-Life Approximately 7–9 Days
Drug Class Androgen & Anabolic Steroid
Manufacturer British Dragon
British Dragon Pharmaceuticals
Product Information Compound Details
Active Formula Testosterone Blend
350 mg/mLTestosterone Propionate 42 mg
Testosterone Isocaproate 84 mg
Testosterone Phenylpropionate 84 mg
Testosterone Decanoate 140 mg
Total Strength 350 mg/mL
Package 10 mL Vial 3,500 mg total labeled content
Form Oil-Based Injectable
Formula 4-Ester Testosterone Blend
Drug Class Androgen & Anabolic Steroid
Manufacturer British Dragon
British Dragon Pharmaceuticals
Product Information
Compound Details
Active Substance
Clomiphene Citrate
Selective Estrogen Receptor Modulator (SERM)
50 mg
Strength
50 mg/tablet
Package
50 or 100 Tablets
Form
Oral Tablets
Drug Class
SERM
Selective Estrogen Receptor Modulator
Estimated Half-Life
Approximately 5–7 Days
Manufacturer
British Dragon